← Back to Screener
Vyome Holdings, Inc. Common Stock (HIND)
Price$2.35
Favorite Metrics
Price vs S&P 500 (26W)-65.16%
Price vs S&P 500 (4W)-12.56%
Market Capitalization$15.51M
All Metrics
Book Value / Share (Quarterly)$0.41
P/TBV (Annual)9.13x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-69.47%
Cash Flow / Share (Quarterly)$-0.63
Price vs S&P 500 (YTD)-39.89%
Gross Margin (TTM)54.41%
Net Profit Margin (TTM)-445.77%
EPS (TTM)$63.63
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$63.63
Revenue Growth (5Y)-27.44%
EPS (Annual)$-4.75
ROI (Annual)-420.22%
Gross Margin (Annual)68.43%
Net Profit Margin (5Y Avg)-861.11%
Cash / Share (Quarterly)$0.84
Revenue Growth QoQ (YoY)-97.98%
ROA (Last FY)-157.95%
Revenue Growth TTM (YoY)-69.70%
EBITD / Share (TTM)$-6.55
ROE (5Y Avg)-452.03%
Operating Margin (TTM)-613.04%
Cash Flow / Share (Annual)$-0.63
P/B Ratio6.35x
P/B Ratio (Quarterly)7.95x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)4.34x
Net Interest Coverage (TTM)-89.22x
ROA (TTM)-148.90%
EPS Incl Extra (Annual)$-4.75
Current Ratio (Annual)1.99x
Quick Ratio (Quarterly)1.86x
3-Month Avg Trading Volume0.61M
52-Week Price Return-93.92%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.36
P/S Ratio (Annual)48.52x
Asset Turnover (Annual)0.05x
52-Week High$56.36
Operating Margin (5Y Avg)-878.19%
EPS Excl Extra (Annual)$-4.75
26-Week Price Return-56.41%
Quick Ratio (Annual)1.86x
13-Week Price Return-26.82%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.99x
Enterprise Value$10.529
Revenue / Share Growth (5Y)-73.32%
Asset Turnover (TTM)0.33x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.95x
Pretax Margin (Annual)-3277.25%
Cash / Share (Annual)$0.84
3-Month Return Std Dev116.15%
Gross Margin (5Y Avg)63.49%
Net Income / Employee (TTM)$-1
ROE (Last FY)-420.22%
Net Interest Coverage (Annual)-276.86x
EPS Basic Excl Extra (Annual)$-4.75
Receivables Turnover (TTM)6.14x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$63.63
Receivables Turnover (Annual)0.65x
ROI (TTM)-359.59%
P/S Ratio (TTM)6.39x
Pretax Margin (5Y Avg)-875.45%
Revenue / Share (Annual)$0.15
Tangible BV / Share (Annual)$0.36
Price vs S&P 500 (52W)-129.01%
Year-to-Date Return-35.76%
5-Day Price Return-4.74%
EPS Normalized (Annual)$-4.75
ROA (5Y Avg)-189.71%
Net Profit Margin (Annual)-3209.79%
Month-to-Date Return2.79%
EBITD / Share (Annual)$-4.79
Operating Margin (Annual)-3269.39%
LT Debt / Equity (Annual)0.09x
ROI (5Y Avg)-447.58%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$63.63
P/TBV (Quarterly)9.13x
P/B Ratio (Annual)7.95x
Inventory Turnover (TTM)0.83x
Pretax Margin (TTM)-454.05%
Book Value / Share (Annual)$0.41
Price vs S&P 500 (13W)-29.69%
Beta1.52x
Revenue / Share (TTM)$0.41
ROE (TTM)-359.59%
52-Week Low$1.75
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
HINDVyome Holdings, Inc. Common Stock | 6.39x | -69.70% | 54.41% | — | $2.35 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Vyome Holdings Inc operates as a biotechnology and pharmaceutical company with two core segments. The company manufactures and distributes antifungal pharmaceutical products while advancing a pipeline of novel biotech therapies (VT-1953, VT-1908, and VB-1953) in development.